BOLT
Bolt Biotherapeutics, Inc.
There isn't enough reported data to score BOLT yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BOLT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Unavailable | |
| Unavailable |
BOLT's revenue is currently healthy, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BOLT PE Valuation
BOLT has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BOLT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect BOLT's losses to shrink, with revenue declining.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BOLT Earnings Per Share
BOLT and HIMS do not have enough comparable growth data to identify a winner.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BOLT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5K | -100% |
| Q1 2026 | $26K | -98% |
| Q3 2025 | $2.2M | +90% |
| Q2 2025 | $1.8M | +41% |
| Q1 2025 | $1.2M | -77% |
| Q3 2024 | $1.1M | -55% |
| Q2 2024 | $1.3M | -11% |
| Q1 2024 | $5.3M | +189% |
BOLT's revenue is growing: $5,000 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -167480% | -166970 points |
| Q1 2026 | -29235% | -28243 points |
| Q4 2025 | -283% | N/A |
| Q3 2025 | -355% | +1086 points |
| Q2 2025 | -511% | +1262 points |
| Q1 2025 | -991% | -667 points |
| Q3 2024 | -1441% | -722 points |
| Q2 2024 | -1772% | -388 points |
BOLT's operating margin was −167480% last quarter, down 166969 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BOLT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over BOLT on profitability, with a higher operating margin.
BOLT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$8M | +$5.3M |
| Q4 2025 | -$7.2M | +$7.3M |
| Q2 2025 | -$9.6M | +$6.5M |
| Q1 2025 | -$13.4M | +$3.4M |
| Q4 2024 | -$14.4M | -$159K |
| Q3 2024 | -$14M | +$2.9M |
| Q2 2024 | -$16.1M | -$998K |
| Q1 2024 | -$16.8M | +$6.7M |
BOLT has the stronger cash trend. Its trailing FCF is up 38% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
BOLT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +10.1K shares |
| 1 year | -12% | -227K shares |
| 3 years | -10% | -197K shares |
| 5 years | -7.6% | -139K shares |
BOLT has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BOLT Net Leverage
BOLT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BOLT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.2 | Neutral |
| Stochastic | 69.4 | Neutral |
BOLT's weekly RSI is 61 (neutral) and its Stochastic is 69 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BOLT PE vs Healthcare Sector
BOLT has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BOLT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.06 | 17% above |
| 20 week MA | $4.34 | 36% above |
| 50 week MA | $4.74 | 25% above |
| 100 week MA | $5.88 | 0.5% above |
| 200 week MA | $13.8 | 57% below |
BOLT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BOLT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $643.0 | $94.6 | -85% |
| 2022 | $94.6 | $26.0 | -73% |
| 2023 | $26.0 | $22.4 | -14% |
| 2024 | $22.4 | $10.4 | -54% |
| 2025 | $10.4 | $5.33 | -49% |
| 2026 YTD | $5.33 | $5.91 | +11% |
BOLT has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.